$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
Clostridium difficile is a gram positive, spore-forming bacterium, causing approximately 500,000 infections annually in the US and is considered a threat level urgent pathogen by the Centers for Disease Control and Prevention (CDC), the highest level of risk.1 The past decade has seen considerable drug development in antimicrobials with activity against C. difficile.2,3In vitro studies are a necessary component of the drug development process.4 Traditionally, in vitro susceptibility and time kill studies are used to validate future animal and other in vivo studies.
While these methods serve an important role for evaluating killing action, they do not capture the cells' phenotypic response to pharmacological treatment. By incorporating scanning electron microscopy (SEM) with standard killing kinetic studies, a more thorough characterization of the antibiotic direct effects is possible.5,6,7 Here, we present a method where SEM is used as a means to profile the efficacy of antibiotic treatment.